EDITORIAL article

Front. Neurol., 13 January 2014

Sec. Neurodegeneration

Volume 5 - 2014 | https://doi.org/10.3389/fneur.2014.00001

“Tau Oligomers,” What We Know and What We Don’t Know

  • 1. Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan

  • 2. Centro de Biologia Molecular Severo Ochoa (CSIC-UAM), Madrid, Spain

Neurofibrillary tangles, composed of intracellular aggregates of tau protein, are a key neuropathological feature of Alzheimer’s disease and other neurodegenerative diseases, collectively termed tauopathies. Tau research has become one of the central players in the investigation of neurodegenerative diseases. Tau protein has several unique characteristics such as natively unfolded conformation, thermo-stability, acid-stability, and capability of post-translational modifications. We still do not know whether tau itself is toxic. With certain triggers, tau may transit into toxic forms. Researchers are now looking for “tau oligomers” as toxic components. Because “tau oligomers” contain variable species of tau protein [e.g., dimer (disulfide bond-dependent or -independent), multimer (more than dimer), granular (defined as EM or AFM) and perhaps small filamentous aggregates] (Figure 1), it is important to have a consensus regarding the definition, terminology, and methodology for the identification of “tau oligomers” (16).

Figure 1

Recently, “prion-like” toxicity and propagation mechanisms underlying the progression of disease have been proposed. With this concept, tau may have the ability to translocate between neurons and amplify toxic components (7). Although we do not know the exact forms of toxic tau oligomers, accumulating evidence has shown the probability of tau oligomer propagation (6).

Tau is an intracellular microtubule-associated protein. The mechanism of tau transmission from cell to cell is still unknown. Research focusing on extracellular tau will open potential new avenues for discovering the mechanism of tau propagation (8).

Abnormally hyperphosphorylated tau is a key feature of human tauopathies. Although we are not sure whether phosphorylation rather than oligomerization of tau is an initial molecular event in tau pathogenesis, investigating the regulatory mechanisms of tau phosphorylation will be essential (911).

Here, we provide an overview of the current understandings of “tau oligomers” (112). Efforts toward the identification of neurotoxic tau species will ultimately lead to the translational research for developing novel therapeutic strategies for tauopathies.

References

Summary

Keywords

tau protein, tauopathy, neurodegenerative disease, propagation, tau phosphorylation

Citation

Sahara N and Avila J (2014) “Tau Oligomers,” What We Know and What We Don’t Know. Front. Neurol. 5:1. doi: 10.3389/fneur.2014.00001

Received

19 December 2013

Accepted

02 January 2014

Published

13 January 2014

Volume

5 - 2014

Edited by

Wendy Noble, King’s College London, UK

Copyright

*Correspondence:

This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neurology.

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics